<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=118459&amp;fmt=gif">
Show all

At-Home Antiviral COVID-19 Pill Authorized

At-Home Antiviral COVID-19 Pill

1.5 minute read

The Food and Drug Administration (FDA) has issued an emergency use authorization for an antiviral pill intended to help treat COVID-19 cases.

Paxlovid, by Pfizer, is authorized for at-home use. Individuals ages 12 and up can take the prescription-only pill as soon as they are diagnosed with COVID-19 and within five days of symptom onset. The pill is intended to treat COVID-19 before getting sick enough to require hospitalization. According to Pfizer, the treatment cut the risk of hospitalization or death by 88% among high-risk unvaccinated individuals when administered a few days after seeing symptoms.

The FDA stressed the pill is not a substitute for the vaccine, is not authorized for COVID-19 pre- or post-exposure prevention, and it not a substitute for treatment among those who need hospitalization. Paxlovid is only intended to help reduce the seriousness of the COVID-19 infection, not preventing infection in the first place.

Download the bulletin for more details.

New Call-to-action

This blog is intended to be a compilation of information and resources pulled from federal, state, and local agencies. This is not intended to be legal advice. For up to the minute information and guidance on COVID-19, please follow the guidelines of the Centers for Disease Control and Prevention (CDC) and your local health organizations.

National Insurance Services is not a law firm and no opinion, suggestion, or recommendation of the firm or its employees shall constitute legal advice. Readers are advised to consult with their own attorney for a determination of their legal rights, responsibilities and liabilities, including the interpretation of any statute or regulation, or its application to the readers’ business activities.

Coronavirus: Third Leading Cause of Death in 2020
January 10, 2022
PCORI Fee Adjusted for 2022
January 10, 2022
Ashley Veenendaal

Ashley Veenendaal

Ashley Veenendaal’s energy and enthusiasm are the first things you notice about her. She’s a problem solver who doesn’t mind going out of her way to help a customer. “I aim to provide the solution that works for them,” says Ashley, “not the one that’s easiest for me.” Ashley has worked at National Insurance Services in a variety of positions including the Billing, Underwriting, and the (Customer) Service Department. As the Full Benefits Consulting (FBC) Service Supervisor, she oversees the FBC Client Relations team, streamlining and improving implementation processes, and working on various departmental projects. Ashley is a licensed insurance agent with a Group Benefits Disability Specialist (GBDS) designation.